

Alicante, January 13th, 2025

COMMUNICATION- OTHER RELEVANT INFORMATION - FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Pursuant to Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation), and section 4.5.1 of Euronext Growth Markets Rule Book Part I: Harmonized Rules, on ongoing obligations of companies listed on Euronext, (hereinafter “FacePhi” or “the Company”) hereby notifies the following:

The Company published, on May 13th, 2024, a communication of “Inside Information” regarding the agreement reached with Nice & Green for the cancellation of new convertible bond issuances (the initial investment agreement was notified to the market on May 5th, 2023, and the amendments communicated on January 19th, 2024).

On the communication from May 13th, it was also confirmed that the terms of exchange and conversion for the tranches already issued were maintained.

Consequently, Nice & Green, under the terms of the investment agreement, has notified the Company of its right to convert 60 Notes (corresponding to the 4th Tranche 2024) for a conversion amount of €600,000.

As a result of the above, the Company will grant a capital increase title deed to cover the conversion of the Notes. A total of 365,163 new shares of the Company will be issued with an issuance price of €1.6431 per share (€0.04 euros of nominal value plus issue premium €1.6031).

Once the capital increase title deed is granted, the share capital will be set at the sum of €1,031,063.36 represented by 25,776,709 shares of €0.04 nominal value each, numbered from 1 to 25,776,709, of the same class, equal, cumulative and indivisible.

Following the exercise of these 60 convertible bonds carried out by Nice & Green, the 4th tranche has been redeemed, and no convertible bonds remain pending conversion.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró

Chairman of the Board of Directors